Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Editorial Note: Olmesartan Potentiates the Anti-Angiogenic Effect of Sorafenib in Mice Bearing Ehrlich’s Ascites Carcinoma: Role of Angiotensin (1–7)

  • The PLOS ONE Editors

Concerns have been raised about discrepancies in the methods and results between this article [1] and a related thesis by the first author [2]. In response, the first author stated that the discrepancies are due to errors in [2]. The first author also provided the underlying data for this article [S1S9 Files] and additional information on the antibodies used in [1] (Table 1). The VEGFR2 antibody details were not clarified.

A member of the Editorial Board reviewed the concerns and authors’ responses, and was satisfied with the responses, but noted that hematoxylin & eosin (H&E) staining is mentioned in the Materials and Methods in [1] but is not shown.

Supporting information

S1 File. Individual-level quantitative data underlying the tumor weight results in [1].

https://doi.org/10.1371/journal.pone.0316407.s001

(XLSX)

S2 File. Individual-level quantitative data underlying the Serum VEGF results in [1].

https://doi.org/10.1371/journal.pone.0316407.s002

(XLSX)

S3 File. Individual-level quantitative data underlying the Serum IGF-I results in [1].

https://doi.org/10.1371/journal.pone.0316407.s003

(XLSX)

S4 File. Individual-level quantitative data underlying the VEGFR2 results in [1].

https://doi.org/10.1371/journal.pone.0316407.s004

(XLSX)

S5 File. Individual-level quantitative data underlying the IGF-IR results in [1].

https://doi.org/10.1371/journal.pone.0316407.s005

(XLSX)

S6 File. Individual-level quantitative data underlying the CD31 results in [1].

https://doi.org/10.1371/journal.pone.0316407.s006

(XLSX)

S7 File. Underlying images supporting the VEGFR results in [1].

https://doi.org/10.1371/journal.pone.0316407.s007

(RAR)

S8 File. Underlying images supporting the IGFR results in [1].

https://doi.org/10.1371/journal.pone.0316407.s008

(RAR)

S9 File. Underlying images supporting the CD31 results in [1].

https://doi.org/10.1371/journal.pone.0316407.s009

(RAR)

References

  1. 1. Abd-Alhaseeb MM, Zaitone SA, Abou-El-Ela SH, Moustafa YM (2014) Olmesartan Potentiates the Anti-Angiogenic Effect of Sorafenib in Mice Bearing Ehrlich’s Ascites Carcinoma: Role of Angiotensin (1–7). PLoS ONE 9(1): e85891. https://doi.org/10.1371/journal.pone.0085891 pmid:24465768
  2. 2. Abd-Alhaseeb El-Mahdy MM (2010) Anti-angiogenic effect of the AT1R blocker, Olmesartan, in addition to sorafenib in in-vivo and in-vitro models of cancer. PhD thesis, Suez Canal University